share_log

HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $95 Price Target

HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $95 Price Target

HC Wainwright & Co.重申買入Denali Therapeutics,維持95美元的目標股價
Benzinga ·  05/08 09:11

HC Wainwright & Co. analyst Andrew Fein reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $95 price target.

HC Wainwright & Co.分析師Andrew Fein重申買入Denali Therapeutics(納斯達克股票代碼:DNLI)並維持95美元的目標價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論